Poseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note released on Thursday morning, Benzinga reports. They currently have a $20.00 price objective on the stock.

Poseida Therapeutics Price Performance

Shares of PSTX stock traded up $0.08 on Thursday, hitting $2.87. 549,987 shares of the stock traded hands, compared to its average volume of 696,517. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.18 and a quick ratio of 3.18. Poseida Therapeutics has a 52 week low of $1.54 and a 52 week high of $4.27. The firm has a 50 day simple moving average of $2.96 and a two-hundred day simple moving average of $2.94. The firm has a market cap of $278.19 million, a price-to-earnings ratio of -2.06 and a beta of 0.46.

Poseida Therapeutics (NASDAQ:PSTX) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative return on equity of 94.90% and a negative net margin of 190.76%. The business had revenue of $25.00 million for the quarter, compared to analysts’ expectations of $12.50 million. As a group, equities research analysts predict that Poseida Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Silverarc Capital Management LLC boosted its holdings in shares of Poseida Therapeutics by 21.1% during the 3rd quarter. Silverarc Capital Management LLC now owns 3,567,985 shares of the company’s stock valued at $8,492,000 after purchasing an additional 622,037 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Poseida Therapeutics by 186.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,857 shares of the company’s stock valued at $816,000 after purchasing an additional 223,280 shares during the last quarter. MCF Advisors LLC grew its stake in shares of Poseida Therapeutics by 476.4% in the 4th quarter. MCF Advisors LLC now owns 247,024 shares of the company’s stock worth $830,000 after buying an additional 204,170 shares in the last quarter. Blair William & Co. IL increased its holdings in shares of Poseida Therapeutics by 30.2% in the 3rd quarter. Blair William & Co. IL now owns 740,650 shares of the company’s stock worth $1,763,000 after buying an additional 171,910 shares during the last quarter. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of Poseida Therapeutics during the 4th quarter valued at about $169,000. 46.87% of the stock is currently owned by institutional investors.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.